Anti-chemokine therapy for inflammatory diseases.
Chemokines are inflammatory proteins acting via G-protein coupled chemokine receptors that trigger different signaling pathways. Monocyte chemoattractant protein-1 (CCL2/MCP-1) and regulated on activation, normal T expressed and secreted (CCL5/RANTES) are the two major members of the CC chemokine beta subfamily. The roles of RANTES and MCP-1 are emerging in regulating the recruitment of inflammatory cells into tissue during inflammation. The inhibition of MCP-1 and RANTES with corresponding antibodies or other inhibitors may provide benefits in different clinical scenarios including cancer, inflammation, CNS disorders, parasitic disease, autoimmune and heart diseases. RANTES and MCP-1 may represent targets for diagnostic procedures and therapeutic intervention, and may be useful as a prognostic factor in the above diseases.
Castellani
M L
ML
Department of Internal Medicine and Science of Ageing, University of Chieti, Italy. mlcastellani@unich.it
Bhattacharya
K
K
Tagen
M
M
Kempuraj
D
D
Perrella
A
A
De Lutiis
M
M
Boucher
W
W
Conti
P
P
Theoharides
T C
TC
Cerulli
G
G
Salini
V
V
Neri
G
G
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors / Q000276:immunology; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors / Q000276:immunology; D018925:Chemokines / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D018925:Chemokines